A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin
compared to placebo in patients with Parkinson's disease psychosis (PDP).